طب الأعصاب

بالأسفل التجارب السريرية الحالية.

غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.

1. A Study to Evaluate Quantitative Phenotypes of Movement Disorders

   Jacksonville, Fla.

   The purpose of this study is to determine if adaptive rhythmic auditory stimulation (ARAS) is a safe means of improving gait; i.e., fewer falls, abrupt accelerations/decelerations in patients with movement disorders. Furthermore, we aim to provide patients with a safe environment in which they can safely navigate through an enjoyable experience (guided art tour) that provides exercise, social engagement, and exposure to art.

2. A Study to Evaluate Pluripotent Stem Cell Models for Spinal Muscular Atrophy (SMA) Patients

   Rochester, Minn., La Crosse, Wis., Jacksonville, Fla.

   The purpose of this study is to perform RNA sequencing on induced pluripotent stem cells (iPSC).  By comparing the gene expression of motor neurons derived from iPSC cells of phenotypically discordant Spinal Muscular Atrophy (SMA) sibling pairs and individual cases of SMA, we hope to identify potential protective gene modifiers of SMA.   Identifying protective gene modifiers will increase our understanding of the molecular pathogenesis of SMA.

3. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC).

4. A Study to Analyze NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with temozolomide (TMZ) in patients with diffuse gliomas at first relapse (Phase I),  and to determine the antitumor effectiveness of the combination of NMS-03305293 and TMZ in patients with isocitrate dehydrogenase (IDH) wild type glioblastoma at first relapse as measured by the 6-month Progression Free Survival (PFS) rate (Phase II).

5. A Study to Assess Neuroinflammation in Epileptic Tissue Immediately Prior to Surgical Resection Using Intraoperative Brain Microdialysis

   Rochester, Minn.

   The purpose of this study is to measure the space and time characteristics of inflammatory mediator release in response to induced epileptiform activity in ASD-resistant patients.

6. A Study of the Thalamus Using Deep Electrode EEG to Better Understand its Participation in the Beginning or Spreading of Seizures

   Rochester, Minn.

   The purpose of this study is to assess the thalamus area of the brain using stereotactic electroencephalography (an EEG with deep electrode placement inside the brain) to better understand its role in the starting and spreading of epileptic seizure activity.

7. PLS Natural History Study

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to develop a natural history dataset and biorepository of early Primary Lateral Sclerosis (PLS) and well-established PLS cases for future clinical trials.

8. A Study to Develop and Assess the Role of Artificial Intelligence in MR Fingerprinting of the Brain

   Rochester, Minn.

   The purpose of this study is to develop an artificial intelligence (AI) system than can process MR images acquired using conventional acquisition schemes (spin echo, gradient echo, etc) and contrasts (T1, T2, T2*, PD) to identify the MR fingerprint of the tissue under interrogation.

9. A Study to Evaluate MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with Amyotrophic Lateral Sclerosis (ALS)

   Jacksonville, Fla.

   The purpose of this study is to evaluate the effectiveness, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

10. A Study to Evaluate Droperidol Use in the Emergency Department and the Effect on QTc

    Rochester, Minn.

    The purpose of this study is to study the length of the QTc interval in patients receiving the standard of care dose of intravenous droperidol for headache or migraine, nausea, pain, and indications other than agitation over 30 minutes.